Cohen Ilana
Immunity Pharma Ltd., Israel
Biography
Ilana Cohen earned her Ph.D. in neurobiology at the Weizmann Institute of Science, Israel. She has more than 20 years of experience in scientific management of drug development, leading multidisciplinary projects from initial drug discovery stages to clinical trials. As part of Immunity Pharma (IPL) management her main goal is helping people living with neurodegenerating disorders by developing innovative therapies. She leads the development of Immunity Pharma’s novel technology platform that focuses on receptor-independent activation of the pro-survival Akt pathway, a key pathway in preventing neurodegeneration. IPL's first drug candidate targets Amyotrophic Lateral sclerosis (ALS) is currently evaluated in exploratory open label Phase 2a clinical trial with ALS patients.
Abstract
Abstract : Peptide IPL344, an AKT activator, treats SOD1 ALS model mice to improve neuro-muscular function